Prenatal alcohol exposure (PAE) has been shown to induce symptomatology associated with
attention deficit hyperactivity disorder (
ADHD) by altering neurodevelopmental trajectories. Phosphodiesterase-1 (PDE1) is expressed centrally and has been used in various experimental brain conditions. We investigated the role of
vinpocetine, a PDE1 inhibitor, on behavioral phenotypes and important biochemical deficits associated with a PAE rat model of
ADHD.
Protein markers of cerebral health (
synapsin-IIa,
BDNF, and pCREB),
inflammation (IL-6, IL-10, and TNF-α), and oxidative stress (
TBARS, GSH, and SOD) were analyzed in three brain regions (frontal cortex, striatum, and cerebellum). Hyperactivity, inattention, and anxiety introduced in the offspring due to PAE were assayed using open-field, Y-maze, and elevated plus maze, respectively. Administration of
vinpocetine (10 & 20 mg/kg, p.o. [by mouth]) to PAE rat offspring for 4 weeks resulted in improvement of the behavioral profile of the animals. Additionally, levels of
protein markers such as
synapsin-IIa,
BDNF, pCREB,
IL-10, SOD, and GSH were found to be significantly increased, with a significant reduction in markers such as TNF-α,
IL-6, and
TBARS in selected brain regions of
vinpocetine-treated animals.
Vinpocetine, a selective PDE1 inhibitor, rectified behavioral phenotypes associated with
ADHD, possibly by improving cerebral function, reducing
brain inflammation, and reducing brain oxidative stress. This study provides preliminary analysis and suggests that the PDE1
enzyme may be an important pharmacological tool to study
ADHD as a result of PAE.